Solna,
The need for safe and effective cancer treatment in dogs is vast and increasing as the number of pets grows. There are 90 million dogs in the US and 93 million dogs in the EU in 2021, with approximately 1.5 million dogs developing cancer in each market per year. There are currently few approved drugs for the treatment of cancer in dogs and current paclitaxel formulations are not tolerated by dogs and therefore cannot be used.
"The veterinary oncology drugs available today are not always developed for use in pets and may be associated with side effects and lack of efficacy. With Paccal Vet, we address an area with great medical need for better treatment options and a rapidly growing market. A thorough review of previous clinical studies with Paccal Vet have demonstrated favorable efficacy and safety. By changing the treatment strategy and moving into indications with great medical need, we have overall an attractive development situation and hopefully a relatively quick route to market. We are now looking forward to starting the clinical development with the goal of being able to include the first patient during the fall," said
About hemangiosarcoma in dogs
Hemangiosarcoma is one of the most common malignant cancers in dogs and is associated with a poor prognosis, with less than 10% of dogs surviving 12 months. The number of dogs diagnosed with hemangiosarcoma annually in the US and
Treatment options for hemangiosarcoma include surgery and adjuvant chemotherapy. The median survival time for dogs with hemangiosarcoma of the spleen undergoing surgery alone is approximately 3 months. Chemotherapeutic agents are used to manage residual metastatic disease after surgery. The most common chemotherapy programs in use today can extend survival with hemangiosarcoma of the spleen by an average of 6.5 months.
About malignant melanoma in dogs
The number of dogs diagnosed with malignant melanoma annually in the US and
Malignant melanomas are highly proliferative, spreading primarily to local lymph nodes and lungs. Surgery and/or radiotherapy are the main treatment options today and target local disease, therefore metastatic disease is still the main cause of death for dogs with malignant melanoma. Consequently, chemotherapy is also considered for the treatment of metastatic and non-operable melanoma. Between 20-30% respond to currently available treatment.
For More Information:
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About
© Modular Finance, source